Board and Management
Co-founder and CEO: Ass. Prof. Dr. Volker M. Lauschke, PhD, BBA
Volker obtained his PhD from the EMBL and the Combined Faculty of Natural Sciences and Mathematics of the University of Heidelberg, Germany for the development of a novel primary cell culture system and his work on tissue patterning based on phase-encoding using molecular oscillators. In 2014, he moved to Karolinska Institutet as a MarieCurie fellow to work on the development of physiological hepatic model systems. He is Assistant Professor for Liver function and regeneration with emphasis on drug development since Jan. 2017. His research is focused on hepatic toxicity and disease models, hepatocyte differentiation plasticity in health and disease as well as the genetic basis of drug response.
In addition, Volker obtained a BBA degree from the University of Hagen, Germany, and has successfully completed academic courses Law.
Co-founder and Chairman of the Board: Prof. Magnus Ingelman-Sundberg, PhD, BSc Med.
Magnus Ingelman-Sundberg: BSc in Medicine, PhD and Docent in Physiological Chemistry, Professor of Molecular Toxicology at Karolinska Institutet, Stockholm Sweden. Member of several Editorial Advisory Boards and recipient of multiple awards in the field of drug metabolism and toxicity. More than 440 original papers, 26 000 citations and an h-factor of 85. Member of The Nobel Assembly at Karolinska Institutet since 2008. Recently categorized by Thomson Reuters as one of the World’s Most Influential Scientific Minds.